logo-loader
viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals posts strong revenue numbers, trend to continue in 2019

Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive Investors the Canadian company posted fiscal fourth-quarter results, with revenue that more than quintupled year-over-year.

d’Entremont says the drug-maker saw revenue jump to $12.7 million, up from $2.1 million in the prior-year quarter due to its recent M&A activity and revenues coming from its pharma products.

Quick facts: Medexus Pharmaceuticals Inc

Price: 3.75 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $53.03 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Discovery Investment Research analyst says Medexus...

James Gentrup, Senior Equity Analyst at micro-cap research firm Discovery Investment Research tells Proactive he thinks Canada-based Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQB:PDDPF) has a "solid" business with the company's single-dose auto-injector of methotrexate for the treatment of...

on 26/8/19

2 min read